Perpetua Resources 株価情報 (NASDAQ: PPTA)

最新ニュース Perpetua Resources (NASDAQ:PPTA) 株価情報

Perpetua Resources

Perpetua Resources Corp is focused on the exploration, site restoration, and redevelopment of gold-antimony-silver deposits in the Stibnite-Yellow Pine district of central Idaho that are encompassed by the Stibnite Gold Project. The Project is one of the highest-grade, open-pit gold deposits in the United States and is designed to apply a modern, responsible mining approach to restore an abandoned mine site and produce both gold and the only mined source of antimony in the United States. It has one segment, mineral exploration in the United States.

Perpetua Resources Corp

Datadog (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDOG#NASDAQ">DDOG</a>) raises FY2025 Adj EPS guidance from $1.65-$1.70 to $1.67-$1.71 vs $1.75 analyst estimate. Raises FY2025 sales outlook from $3.17 billion-$3.19 billion to $3.21 billion-$3.23 billion vs $3.20 billion estimate.

News

Guidance

DDOG

Datadog Raises FY2025 Adj EPS Guidance from $1.65-$1.70 to $1.67-$1.71 vs $1.75 Est; Raises FY2025 Sales Guidance from $3.17B-$3.19B to $3.21B-$3.23B vs $3.20B Est

<ul>
<li>First patent significantly advances intellectual property for HeartBeam's credit card-sized ECG device, bolstering both the defensive and offensive moat around the company's core technology</li>
<li>Second patent expands the use of risk-based diagnostic algorithms into HeartBeam's product portfolio around wearable devices</li>
<li>HeartBeam now has 20 issued patents worldwide, cementing Company's leadership in cardiac monitoring innovation</li>
</ul>
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.heartbeam.com%2F&amp;esheet=54249202&amp;newsitemid=20250506303008&amp;lan=en-US&amp;anchor=HeartBeam%2C+Inc.&amp;index=1&amp;md5=ad0e0f6a02ff4a461ad100d46e36c059">HeartBeam, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAT#NASDAQ">BEAT</a>), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced the addition of two new U.S. patents, reinforcing its core intellectual property position and enabling future product extensions. The patents reinforce HeartBeam's groundbreaking innovations and further solidify the Company's intellectual property (IP) footprint in cardiac monitoring technology that bring advanced cardiac insights to patients and clinicians.
The first patent protects IP around HeartBeam's credit card-sized, cable-free 3D ECG device. Designed for ease of use, the device features chest and finger electrodes to capture high-fidelity electrical signals in 3D (by capturing 3 non-coplanar directions) – enabling patients to record their symptoms the moment they occur, wherever they are. The signals are then synthesized into a familiar 12-lead ECG using a personalized transformational matrix. The 12-lead ECG synthesis software is currently under review with the FDA. <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.heartbeam.com%2Fnews-events%2Fpress-releases%2Fdetail%2F92%2Fheartbeam-successfully-meets-clinical-endpoints-in-pivotal&amp;esheet=54249202&amp;newsitemid=20250506303008&amp;lan=en-US&amp;anchor=Data+from+the+VALID-ECG+pivotal+study&amp;index=2&amp;md5=7ef3c476ceaaffb653e88c996c591cc0">Data from the VALID-ECG pivotal study</a> supporting the FDA submission was presented at the Heart Rhythm Society conference in April 2025.
The second patent protects HeartBeam's rhythm analysis algorithm, which distinguishes between sinus rhythm, atrial fibrillation, and other arrhythmias using continuous signal input. Designed to operate on any cardiac monitoring system including wearables, the algorithm enables risk-based escalation by detecting anomalies during passive monitoring and prompting the user to collect high-fidelity 3D ECG signals with HeartBeam's credit card-sized device, enabling synthesis of a 12-lead ECG.
"HeartBeam's vision is to make it easier for patients and physicians to monitor and diagnose cardiac symptoms outside of a medical facility. The new patents add to our growing IP portfolio, enabling us to expand the reach and impact of our groundbreaking 3D ECG technology as we strive to transform the future of cardiac care," said Robert Eno, Chief Executive Officer of HeartBeam.
With these two new U.S. patents, HeartBeam now holds 20 issued US and international patents, as well as 2 allowed patents and 32 pending patents, adding to an already robust IP portfolio that supports the company's differentiated position in remote cardiac diagnostics. These innovations lay the groundwork for future capabilities such as AI-driven classification algorithms and ischemia detection, further extending HeartBeam's potential to provide unprecedented cardiac insights to individuals and physicians.

BEAT

HeartBeam Announces It Has Received Two New U.S. Patents

Colliers Intl Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CIGI#NASDAQ">CIGI</a>) reported quarterly earnings of $0.87 per share which beat the analyst consensus estimate of $0.86 by 1.16 percent. This is a 12.99 percent increase over earnings of $0.77 per share from the same period last year. The company reported quarterly sales of $1.14 billion which missed the analyst consensus estimate of $1.15 billion by 0.66 percent. This is a 13.87 percent increase over sales of $1.00 billion the same period last year.

Earnings

Earnings Beats

Earnings Misses

CIGI

Colliers Intl Gr Q1 Adj. EPS $0.87 Beats $0.86 Estimate, Sales $1.14B Miss $1.15B Estimate

Pet Valu Holdings (TSX:<a class="ticker" href="https://www.benzinga.com/stock/PET#TSX">PET</a>) affirms FY2025 Adj EPS guidance from $1.60-$1.66 to $1.60-$1.66 vs $1.62 analyst estimate. Affirms FY2025 sales outlook from $1.17 billion-$1.20 billion to $1.17 billion-$1.20 billion vs $1.18 billion estimate.

TSX:PET

Pet Valu Holdings Affirms FY2025 Adj EPS Guidance of $1.60-$1.66 vs $1.62 Est; Affirms FY2025 Sales Guidance of $1.17B-$1.20B vs $1.18B Est

UL Solutions Q1 Adj. EPS $0.33 Beats $0.30 Estimate, Sales $705.00M Beat $704.18M Estimate

President Donald Trump&#8216;s sweeping budget package faces a bumpy road in Congress as Republican lawmakers work to meet House Speaker Mike Johnson&#8216;s Memorial Day deadline, balancing tax cuts with spending <a href="https://www.benzinga.com/markets/25/04/44916245/congress-could-greenlight-trumps-big-beautiful-tax-bill-by-summer-things-are-moving-very-very-quickly-says-hassett">priorities that have divided the party</a>.
What Happened: The ambitious &#8220;one big, beautiful bill&#8221; combines tax breaks, spending cuts and increased border security funding, with House committees approving portions largely along party lines. Republicans have made most progress on spending increases, approving approximately $350 billion for the Pentagon and Homeland Security, while tax cuts remain unfinished, <a href="https://apnews.com/article/trump-big-bill-tax-cuts-medicaid-1c893945b416419d806dacb6d24b895a">reported</a> the Associated Press on Monday.
&#8220;There are some bumps in the road,&#8221; acknowledged Rep. Jason Smith (R-MO), Chairman of the Ways and Means Committee, on Fox News Sunday.
The immigration portion includes $46.5 billion for border wall construction and $4 billion to hire 3,000 new Border Patrol agents. The plan aims to deport 1 million migrants annually and imposes new fees, including a controversial $1,000 charge for asylum seekers.
Defense spending would increase by $150 billion, including $25 billion for Trump&#8217;s &#8220;Golden Dome&#8221; missile defense system and $21 billion to restock ammunition supplies.
See Also: <a href="https://www.benzinga.com/markets/commodities/25/05/45215302/a-breakout-is-near-as-gold-surges-above-3380-and-silver-starts-to-perk-up-says-peter-schiff">Bitcoin Critic Peter Schiff Says A &#8216;Breakout Is Near&#8217; As Gold Surges Above $3,380, Silver Starts To Perk Up</a>
What Happened: Trump has drawn <a href="https://www.benzinga.com/government/25/04/45064937/donald-trump-threatens-to-veto-any-gop-bill-that-touches-medicaid-or-social-security-if-it-cuts-it-i-would-not-approve">clear boundaries for negotiators</a>, telling TIME Magazine he would veto any bill cutting Social Security or Medicaid. &#8220;If it cuts it, I would not approve,&#8221; Trump said, limiting changes to efforts targeting &#8220;waste, fraud and abuse.&#8221;
Trump has also expressed <a href="https://www.benzinga.com/news/25/04/45107801/trumps-proposed-millionaires-tax-draws-fierce-gop-pushback-doing-so-would-be-political-death-experts">openness to increasing taxes on millionaires</a>, sparking fierce opposition from conservatives. Americans for Tax Reform President Grover Norquist called it a &#8220;really bad idea,&#8221; warning such a move could be &#8220;political death&#8221; for Trump.
According to the Committee for Responsible Federal Budget, <a href="https://www.benzinga.com/government/regulations/25/02/43574215/trumps-tax-plans-could-slash-revenue-by-11-trillion">Trump&#8217;s proposed tax cuts</a> could reduce federal revenue by up to $11.2 trillion over the next decade, potentially pushing U.S. debt to 149% of GDP without offsetting spending reductions.
If House Republicans manage to pass their version, the legislation will face additional hurdles in the Senate, which is drafting its own package with hopes of <a href="https://www.benzinga.com/government/25/04/45064937/donald-trump-threatens-to-veto-any-gop-bill-that-touches-medicaid-or-social-security-if-it-cuts-it-i-would-not-approve">finalizing it before the August recess</a>.
House Democratic Leader Hakeem Jeffries has promised to fight what he calls the &#8220;extreme Republican agenda.&#8221;
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/05/45215281/trump-orders-fda-to-fast-track-us-drug-production-as-tariff-threat-looms-on-imported-medicines-cites-national-security-concerns">Trump Orders FDA To Fast-Track US Drug Production As Tariff Threat Looms On Imported Medicines: Cites National Security Concerns</a></li>
</ul>
Disclaimer: This content was partially produced with the help of <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a> and was reviewed and published by Benzinga editors.
Image Via Shutterstock

Equities

Politics

Economics

Federal Reserve

Markets

TSLA

Trump's 'Big, Beautiful Bill' Takes Shape: GOP Pushes Tax Cuts, Border Wall Funding, And Deep Spending Reductions Ahead Of Memorial Day Deadline

Marriott Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAR#NASDAQ">MAR</a>) reported quarterly earnings of $2.32 per share which beat the analyst consensus estimate of $2.25 by 3.11 percent. This is a 8.92 percent increase over earnings of $2.13 per share from the same period last year. The company reported quarterly sales of $6.26 billion which beat the analyst consensus estimate of $6.17 billion by 1.52 percent. This is a 4.79 percent increase over sales of $5.98 billion the same period last year.

Marriott Intl Q1 Adj. EPS $2.32 Beats $2.25 Estimate, Sales $6.26B Beat $6.17B Estimate

Datadog (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDOG#NASDAQ">DDOG</a>) is looking for Q2 Adj EPS of $0.40-$0.42 vs $0.41 analyst estimate. sees sales of $787.000 million-$791.000 million vs $772.13 million analyst estimate.

Datadog Sees Q2 Adj EPS $0.40-$0.42 vs $0.41 Est; Sees Sales $787.000M-$791.000M vs $772.13M Est

Zoetis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) reported quarterly earnings of $1.48 per share which beat the analyst consensus estimate of $1.39 by 6.47 percent. This is a 7.25 percent increase over earnings of $1.38 per share from the same period last year. The company reported quarterly sales of $2.22 billion which beat the analyst consensus estimate of $2.19 billion by 1.38 percent. This is a 1.37 percent increase over sales of $2.19 billion the same period last year.

Zoetis Q1 Adj. EPS $1.48 Beats $1.39 Estimate, Sales $2.22B Beat $2.19B Estimate

Needham analyst Quinn Bolton reiterates Lattice Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSCC#NASDAQ">LSCC</a>) with a Buy and maintains $70 price target.

Price Target

Reiteration

Analyst Ratings

LSCC

Needham Reiterates Buy on Lattice Semiconductor, Maintains $70 Price Target

NOVT

Novanta Q1 Adj. EPS $0.74 Beats $0.67 Estimate, Sales $233.37M Beat $233.34M Estimate

Willis Lease Finance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLFC#NASDAQ">WLFC</a>) reported quarterly earnings of $2.21 per share which missed the analyst consensus estimate of $3.90 by 43.33 percent. This is a 26.33 percent decrease over earnings of $3.00 per share from the same period last year. The company reported quarterly sales of $157.73 million which beat the analyst consensus estimate of $149.00 million by 5.86 percent. This is a 32.46 percent increase over sales of $119.08 million the same period last year.

WLFC

Willis Lease Finance Q1 EPS $2.21 Misses $3.90 Estimate, Sales $157.73M Beat $149.00M Estimate

PLTR

Palantir, xAI, And TWG Global Collaborate To Enhance AI In Financial Services

Datadog Q1 Adj. EPS $0.46 Beats $0.43 Estimate, Sales $762M Beat $741.52M Estimate

SolarEdge Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>) sees Q2 sales of $265.000 million-$285.000 million vs $247.96 million analyst estimate.

SEDG

SolarEdge Technologies Sees Q2 Sales $265.000M-$285.000M vs $247.96M Est

Market-Moving Exclusives

Exclusives

HFFG

EXCLUSIVE: HF Foods Group Tells Benzinga Co. Rebrands And Launches Innovative E-Commerce Platform Dedicated To International Foodservice Solutions In The U.S.

Telsey Advisory Group analyst Dana Telsey maintains Waldencast (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WALD#NASDAQ">WALD</a>) with a Outperform and maintains $5 price target.

WALD

Telsey Advisory Group Maintains Outperform on Waldencast, Maintains $5 Price Target

Pet Valu Hldgs (TSX:<a class="ticker" href="https://www.benzinga.com/stock/PET#TSX">PET</a>) reported quarterly earnings of $0.36 per share which beat the analyst consensus estimate of $0.34 by 5.88 percent. This is a 2.86 percent increase over earnings of $0.35 per share from the same period last year. The company reported quarterly sales of $279.09 million which beat the analyst consensus estimate of $274.96 million by 1.50 percent. This is a 7.02 percent increase over sales of $260.79 million the same period last year.

Pet Valu Hldgs Q1 Adj. EPS $0.36 Beats $0.34 Estimate, Sales $279.09M Beat $274.96M Estimate

Needham analyst Mike Cikos reiterates ServiceNow (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>) with a Buy and maintains $1050 price target.

Needham Reiterates Buy on ServiceNow, Maintains $1050 Price Target

American Electric Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEP#NASDAQ">AEP</a>) reported quarterly earnings of $1.54 per share which beat the analyst consensus estimate of $1.40 by 10 percent. This is a 21.26 percent increase over earnings of $1.27 per share from the same period last year. The company reported quarterly sales of $5.46 billion which beat the analyst consensus estimate of $5.17 billion by 5.68 percent. This is a 9.26 percent increase over sales of $5.00 billion the same period last year.

American Electric Power Q1 Adj. EPS $1.54 Beats $1.40 Estimate, Sales $5.46B Beat $5.17B Estimate

Press Releases

Perpetua Resources Corp. (PPTA) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

Legal

Investors who lost money on Perpetua Resources Corp.(PPTA) should contact Levi & Korsinsky about pending Class Action - PPTA

PPTA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Perpetua Resources Corp. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Perpetua Resources Shareholders Who Lost Money on Their Investment are Encouraged to Contact Johnson Fistel about the Class Action Lawsuit

PPTA Investors Have Opportunity to Lead Perpetua Resources Corp. Securities Fraud Lawsuit

Class Action Filed Against Perpetua Resources Corp. (PPTA) - May 20, 2025 Deadline to Join - Contact The Gross Law Firm

SHAREHOLDER ALERT: Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Perpetua Resources Corp. (NASDAQ: PPTA)

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Perpetua Resources Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PPTA

Kirby McInerney LLP Urges Investors in Perpetua Resources Corp. (PPTA) to Inquire About Their Rights in Class Action Lawsuit

PPTA LAWSUIT ALERT: Levi & Korsinsky Notifies Perpetua Resources Corp. Investors of a Class Action Lawsuit and Upcoming Deadline

PPTA

HC Wainwright & Co.

Roth MKM

B. Riley Securities

Roth Capital

Screenshot 2025-03-24 at 6.45.04 PM

Emerging Markets

Commodities

Movers & Shakers

UAMY

Antimony Is Critical To American Defense And Tech, But Major Supply Concerns Persist – Nova Minerals Wants To Change That

Screenshot 2025-03-20 at 6.07.18 PM

GOLD

Gold, Antimony And The New Push For American Resource Dominance

Comments

Perpetua Resources

ニュース

最新ニュース Perpetua Resources (NASDAQ:PPTA) 株価情報

ニュース

パートナーシップ

ベンジンガ・グローバル